ArticleFrontiers in pharmacology2020
Total Flavones of
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Efficacy and safety of Abelmoschus manihot in the treatment of patients with type 2 diabetes and microalbuminuria: A multicenter randomized, open-label, parallel-controlled clinical trial.Chinese medical journal · 2026Article
- Autophagy-mediated Kupffer cell polarization in liver cirrhosis reversal: Mechanistic insights and therapeutic strategies.Liver research (Beijing, China) · 2026Review
- Pharmacological potential of Chinese botanical drugs in managing chronic kidney disease by targeting mitochondrial quality control.Frontiers in pharmacology · 2025Review
- Therapeutic potential ofFrontiers in pharmacology · 2025Review
- The dual regulatory effects of intestinal microorganisms and their metabolites in gouty arthritis pathogenesis: a balance between promotion and inhibition.Frontiers in immunology · 2025Review
- Elucidating the role of gut microbiota dysbiosis in hyperuricemia and gout: Insights and therapeutic strategies.World journal of gastroenterology · 2024Review
- Prediction of delayed graft function by early salivary microbiota following kidney transplantation.Applied microbiology and biotechnology · 2024Article
- Review
- Article
- The pharmacological mechanism ofHeliyon · 2023Review
- Peripheral and Central Impact of Methionine Source and Level on Growth Performance, Circulating Methionine Levels and Metabolism in Broiler Chickens.Animals : an open access journal from MDPI · 2023Article
- Abelmoschus Manihot ameliorates the levels of circulating metabolites in diabetic nephropathy by modulating gut microbiota in non-obese diabetes mice.Microbial biotechnology · 2023Article
- Ferroptosis: a new strategy for Chinese herbal medicine treatment of diabetic nephropathy.Frontiers in endocrinology · 2023Review
- Identification of the main flavonoids ofFrontiers in pharmacology · 2023Article
- Exploring the total flavones of Abelmoschus manihot against IAV-induced lung inflammation by network pharmacology.BMC complementary medicine and therapies · 2022Article
- The role of gut microbiota in gout: Is gut microbiota a potential target for gout treatment.Frontiers in cellular and infection microbiology · 2022Review
- The modulation of gut microbiota by herbal medicine to alleviate diabetic kidney disease - A review.Frontiers in pharmacology · 2022Review
- Fucoidan Alleviates Renal Fibrosis in Diabetic Kidney DiseaseFrontiers in pharmacology · 2022Article
- Natural products from plants and microorganisms: Novel therapeutics for chronic kidney diseaseFrontiers in pharmacology · 2022Review
- MALAT1 shuttled by extracellular vesicles promotes M1 polarization of macrophages to induce acute pancreatitis via miR-181a-5p/HMGB1 axis.Journal of cellular and molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, progression of chronic renal failure (CRF) has been closely associated with gut microbiota dysbiosis and intestinal metabolite-derived microinflammation. In China, total flavones of
methods
resultsFor the modified CRF model rats, the administration of TFA and FEB improved renal injury, including renal dysfunction and renal tubulointerstitial lesions; remodeled gut microbiota dysbiosis, including decreased
conclusionIn this study, we demonstrated that TFA, similar to FEB, exerts its renoprotective effects partially by therapeutically remodeling gut microbiota dysbiosis and inhibiting intestinal metabolite-derived microinflammation. This is achieved by adjusting autophagy-mediated macrophage polarization through AMPK-SIRT1 signaling. These findings provide more accurate information on the role of TFA in delaying CRF progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.